Zymeworks(ZYME)
MIDDLETOWN, DEBiotechnology
Focus: Zymeworks is a public biotech company specializing in in silico biologics development with a focus on oncology and immunology programs. The company operates at mid-cap scale with 501–1000 employees and is advancing a pipeline of antibody-drug conjugates and targeted biologics.
Profile data last refreshed 4m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
6-1 this month
Stable — net -1 jobs in 30d
5 added, 6 removed. Backfill posture.
Should You Work at Zymeworks?
AI assessmentZymeworks offers compelling technical and clinical upside for scientists seeking oncology experience, but the sharp financial deterioration demands clarification on business model viability before committing career capital.
Why Work Here
- Advanced platform expertise: Zymeworks' in silico biologics approach offers deep technical experience in rational drug design and structure-based optimization, rare in the biotech sector.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT06555744A Study of ZW191 in Participants With Solid Tumors
Phase 1Help build intelligence for Zymeworks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.